Vineti Stock
Cell & Gene Therapy Software
Sign up today and learn more about Vineti Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Vineti Stock
Vineti is a commercial cloud-based platform to expand patient access to life-saving cells and gene therapies. It is a software solution to drive and scale personalized therapeutic innovation. It solves the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine. Founded in 2016, Vineti is headquartered in San Francisco, California.
Investors
Canaan Partners
Instacart, Snyk, Dragos, Turo, The RealReal, MindTickle, Lending Club, Berkshire Grey, Tomorrow.io, Apartment List
Cardinal Health
Casdin Capital
23andMe, Komodo Health, Genapsys, ORIC Pharmaceuticals, Codiak Biosciences, Vineti
dRx Capital
GE Ventures
View, Pivotal, Virgin Hyperloop One, Omada Health, Desktop Metal, Rethink Robotics, Catalant, Vineti, Syapse, Tamr
HIVE Ventures
Kite Pharma
LifeForce Capital
Cityblock Health, HeartFlow, One Medical, Clover Health, Grand Rounds Health, Vineti, Verge Genomics
Mayo Clinic Ventures
McKesson Ventures
Novartis Pharma
Section 32
Celularity, Freenome, Dialpad, Lime, Metromile, Primer, Vineti, Kobalt, BigHat Biosciences
Threshold
Zymergen, BetterUp, Talkdesk, Remitly, Divvy Homes, Prosper Marketplace, CircleCI, Viz, d.light design, Mythic
Funding History
| February 2017 | $14.1M |
|---|---|
| April 2018 | $33.5M |
| January 2020 | $31K |
| January 2020 | $75.2M |
| July 2020 | $94K |
Management
Chief Executive Officer
Amy DuRoss
Chief Financial Officer
Brett Robertson
Chief Technology Officer
Phil Calvin
Press
techcompanynews - Oct, 30 2020
An Interview With Amy DuRoss, CEO And Co-Founder Of Vinetibusinessinsider - Oct, 17 2020
Here's the pitch deck that convinced Salesforce CEO Marc Benioff to participate in a $33 million Series C extension for Vineti, which makes cloud software to track advanced drug developmentfinsmes - Oct, 15 2020
Vineti Raises $33M; Extends Series C Funding to $68MGlobe Newswire - Jun, 16 2020
Vineti launches new Alliance Network -- and announces a collaboration with Mavens -- to deliver integrated solutions for cell and gene therapiesGlobe Newswire - Feb, 5 2020
Vineti Completes $35 Million in Series C Financing to Industrialize Personalized and High-Value Therapeuticsoutsourcing-pharma - Aug, 1 2019
Lonza, Vineti team up to address risks in the ‘vein-to-vein’ supply chainfinance - Jul, 1 2019
Vineti Awarded as Technology Pioneer by World Economic Forumfiercebiotech - Feb, 25 2019
Autolus taps Vineti to help deliver personalized cell therapiesfiercebiotech - Apr, 16 2018
Vineti bags $34M to support CAR-T logisticsEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
